维普期刊资源整合服务平台（V6.5）

20篇 您的检索式：作者名="LAHU G"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

	题名	作者	年代	出处	被引量
1	DNA mismatch correction in a defined system显示文摘	Lahue R S Au K G Modrich P	1989	Science1989，245，4914：	1
2	Impact of early-season thrips management on reducing the risks of spotted wilt virus and suppressing aphid populations in flue-cured tobacco显示文摘	Mc Pherson R M Stephenson M G Lahue S S	2005	Journal of economic entomology2005，98，1：	1
3	DNA mismatch correction in adefined system 显示文摘	LAHUE R S AU K G MODRICH P	1989	Science1989，245，：	1
4	Effect of fluvoxamine on the phamacokinectics of roflumilast and roflumilast N-oxide显示文摘	yon RICHTER O LAHU G HUENNEMEYER A	2007	Clin Phamacokinet2007，46，7：	1
5	High absolute bioavailability of the new oral phosphodiesterase-4 inhibitor roflumilast显示文摘	Bethke TD Lahu G	2011	Int J Clin Pharmacol Ther2011，49，1：	1
6	Population pharmacokinetic modelling of roflumilast and roflumilast N-Oxide by total phosphodiesterase 4 inhibitory activity and development of a population pharmacodynamic adverse event model 显示文摘	Lahu G H0nnemeyer A Diletti E	2010	Clin Pharmacokinet2010，49，9：	1
7	Steady-state pharmacokinetics of roflumilast and roflumilast N-oxide in patients with mild and moderate liver cirrhosis 显示文摘	Hermann R Nassr N Lahu G	2007	Clin Pharmacokinet2007，46，5：	1
8	Effect of repeated dose of erythromycin on the pharmacokinetics of roflumilast and roflumilast N-oxide 显示文摘	Lahu G Httnnemeyer A Herzog R	2009	Int J Clin Pharmacol Ther2009，47，7：	1
9	High absolute bioavailability of the new oral phosphodiesterase-4 inhibitor roflumilast显示文摘	BETHKE T D LAHU G	2011	Int J Clin Pharmacol Ther2011，49，1：	1
10	Lack of a pharmaeokinetie interaction between steady-state roflumilast and single-dose midazolam in healthy subjects显示文摘	NASSR N LAHU G yon RICHTER O et d	2006	Br J Clin Pharmaeol2006，63，3：	1
11	Population phamlacokinetic modelling of roflumilast and roflumilast N-oxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmacodynamic-adverse event model 显示文摘	Lahu G Hunnemeyer A Diletti E	2010	Clin Pharmacokinet2010，49，9：	1
12	High absolute bioavailability of the new oral phosphodiesterase-4 inhibitor roflumilast 显示文摘	Bethke TD Lahu G	2011	lnt J Clin Pharmacol Ther2011，49，1：	1
13	Steady-state pharmacokinetics of roflumilast and roflumilast N-oxide in patients with mild and moderate liver cirrhosis 显示文摘	Hermann R Nassr N Lahu G	2007	Clin Pharmacokinet2007，46，5：	1
14	Effect of repeated doses of erythromycin on the pharmacokinetics of roflumilast and roflumilast N-oxide 显示文摘	LAHU G HuNNEMEYER A HERZOG R	2009	Int J Clin Pharmacol Ther2009，47，4：	1
15	Effect of single and repeated doses of ketoconazole on the pharmacokinetics of roflumilast and roflumilast N-oxide 显示文摘	LAHU G HuNNEMEYER A VON RICHTER O	2008	J Clin Pharmacol2008，48，11：	1
16	Effect of Steady-State Enoxacin on Single-Dose Pharmacokinetics of Roflumilast and Roflumilast N-Oxide 显示文摘	Lahu G Nassr N Herzog R	2011	J Clin Pharmacol2011，51，4：	1
17	Epithelial NF-r,B orchestrates house dust mite-induced airway inflammation, hyperresponsiveness, and fibrotic remodeling 显示文摘	Tully J E Hoffman S M Lahue K G	2013	Jlmmunol2013，191，12：	1
18	Population pharmaeokinetie modelling of roflumilast and roflumilast Noxide by total phosphodiesterase-4 inhibitory activity and development of a population pharmaeodynamie-adverse event model显示文摘	LAHU G HUNNEMEYER A DILETTI E	2010	Clin Pharmacokinet2010，49，9：	1
19	Localization of ice nucleation activity and the ice C gene product in Pseudomonas syringae and Escharichia coli显示文摘	LINDOW S E LAHUE E GOVINDARAJAN A G	1989	Mol Plant-Microbe Interact1989，，2：	1
20	Pharmacokineticevaluation of roflumilast 显示文摘	LAHU G NASSR N HUNNEMEYER A	2011	Expert Opin Drug Metab Toxicol2011，7，12：	1

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示